Novavax aims at make one billion COVID-19 vaccine doses after buying plant


  • World
  • Wednesday, 27 May 2020

A small bottle labeled with a "Vaccine" sticker is held near a medical syringe in front of displayed "Coronavirus COVID-19" words in this illustration taken April 10, 2020. REUTERS/Dado Ruvic/Illustration

(Reuters) - Novavax Inc is buying a manufacturing plant from privately held Serum Institute of India, the world's largest maker of vaccines by volume, as the U.S. company aims to produce 1 billion doses of its COVID-19 vaccine candidate next year.

The U.S. company said on Wednesday it would buy Czech Republic-based Praha Vaccines, a unit of India's Cyrus Poonawalla Group, which also owns Serum Institute, for $167 million in cash.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In World

This AI-focused chip is powered by light
Study warns users about health information on TikTok
Canada's British Columbia calls off drug decriminalization pilot project
3 killed after building collapses in north Nigeria
Aerosmith frontman Steven Tyler wins dismissal for good of sexual assault lawsuit
Chinese company to build photovoltaic factory in Saudi port
Nearly 23 pct of Canadian population reported food insecurity in 2022
Canada announces investment to grow semiconductor supply chain
U.S. stocks close higher
Feature: Chinese firms eager to showcase new products at Spain seafood fair

Others Also Read